{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:57:58Z","timestamp":1785560278848,"version":"3.56.0"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.2169\/internalmedicine.6383-25","type":"journal-article","created":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T22:08:37Z","timestamp":1767305317000},"page":"2050-2057","source":"Crossref","is-referenced-by-count":1,"title":["Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension"],"prefix":"10.2169","volume":"65","author":[{"given":"Tetsuro","family":"Yokokawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Nishiura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joh","family":"Akama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoyo","family":"Kiko","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomofumi","family":"Misaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"},{"name":"Department of Community Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiomi","family":"Yoshihisa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"},{"name":"Department of Clinical Laboratory Sciences, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakazato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuchika","family":"Takeishi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Fukushima Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Houston BA, Brittain EL, Tedford RJ. Right ventricular failure. N Engl J Med 388: 1111-1125, 2023.","DOI":"10.1056\/NEJMra2207410"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Sanz J, S\u00e1nchez-Quintana D, Bossone E, et al. Anatomy, function, and dysfunction of the right ventricle: <i>JACC<\/i> state-of-the-art review. J Am Coll Cardiol 73: 1463-1482, 2019.","DOI":"10.1016\/j.jacc.2018.12.076"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4: 752-762, 2003.","DOI":"10.1038\/nrn1197"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kosaka Y, Cieslik KA, Li L, et al. 14-3-3\u03b5 plays a role in cardiac ventricular compaction by regulating the cardiomyocyte cell cycle. Mol Cell Biol 32: 5089-5102, 2012.","DOI":"10.1128\/MCB.00829-12"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jia Y, Zhang L, Liu Z, et al. Targeting macrophage TFEB-14-3-3 epsilon interface by naringenin inhibits abdominal aortic aneurysm. Cell Discov 8: 21, 2022.","DOI":"10.1038\/s41421-021-00363-1"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Hu Y, Zhang C, Wang S, et al. 14-3-3\u03b5\/<i>YWHAE<\/i> regulates the transcriptional expression of cardiac sodium channel Na<sub>V<\/sub>1.5. Heart Rhythm 21: 2320-2329, 2024.","DOI":"10.1016\/j.hrthm.2024.05.015"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Qiu Y, Zhou Z, Li Z, et al. Pretreatment 14-3-3 epsilon level is predictive for advanced extranodal NK\/T cell lymphoma therapeutic response to asparaginase-based chemotherapy. Proteomics Clin Appl 11: 1600111, 2017.","DOI":"10.1002\/prca.201600111"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lee EK, Lee YS, Lee H, Choi CY, Park SH. 14-3-3\u03b5 protein increases matrix metalloproteinase-2 gene expression via p38 MAPK signaling in NIH3T3 fibroblast cells. Exp Mol Med 41: 453-561, 2009.","DOI":"10.3858\/emm.2009.41.7.050"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Du J, Liao W, Wang Y, Han C, Zhang Y. Inhibitory effect of 14-3-3 proteins on serum-induced proliferation of cardiac fibroblasts. Eur J Cell Biol 84: 843-852, 2005.","DOI":"10.1016\/j.ejcb.2005.06.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Frangogiannis NG. Fibroblasts and the extracellular matrix in right ventricular disease. Cardiovasc Res 113: 1453-1464, 2017.","DOI":"10.1093\/cvr\/cvx146"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Boucherat O, Yokokawa T, Krishna V, et al. Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. Nat Cardiovasc Res 1: 748-760, 2022.","DOI":"10.1038\/s44161-022-00113-w"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yokokawa T, Nishiura K, Katahira M, et al. Collagen triple helix repeat-containing protein 1 is a novel biomarker of right ventricular involvement in pulmonary hypertension. Can J Cardiol 40: 2281-2288, 2024.","DOI":"10.1016\/j.cjca.2024.04.016"},{"key":"13","unstructured":"13. Nishiura K, Yokokawa T, Ichimura S, et al. Targeting CSF1R attenuates the development of pulmonary arterial hypertension through CCL2. Am J Respir Cell Mol Biol. Forthcoming."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tomita Y, Anzai F, Misaka T, et al. Targeting N-myristoylation through NMT2 prevents cardiac hypertrophy and heart failure. JACC Basic Transl Sci 8: 1263-1282, 2023.","DOI":"10.1016\/j.jacbts.2023.06.006"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Shimauchi T, Boucherat O, Yokokawa T, et al. PARP1-PKM2 axis mediates right ventricular failure associated with pulmonary arterial hypertension. JACC Basic Transl Sci 7: 384-403, 2022.","DOI":"10.1016\/j.jacbts.2022.01.005"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nishiura K, Yokokawa T, Misaka T, et al. Prognostic role of circulating LTBP-2 in patients with dilated cardiomyopathy: a novel biomarker reflecting extracellular matrix LTBP-2 accumulation. Can J Cardiol 39: 1436-1445, 2023.","DOI":"10.1016\/j.cjca.2023.05.015"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ichimura S, Misaka T, Ogawara R, et al. Neutrophil extracellular traps in myocardial tissue drive cardiac dysfunction and adverse outcomes in patients with heart failure with dilated cardiomyopathy. Circ Heart Fail 17: e011057, 2024.","DOI":"10.1161\/CIRCHEARTFAILURE.123.011057"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. de Perrot M, Gopalan D, Jenkins D, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant 40: 1301-1326, 2021.","DOI":"10.1016\/j.healun.2021.07.020"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46: 903-975, 2015.","DOI":"10.1183\/13993003.01032-2015"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Humbert M, Kovacs G, Hoeper MM, et al.; the ESC\/ERS Scientific Document Group. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 61: 2200879, 2023.","DOI":"10.1183\/13993003.00879-2022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Yokokawa T, Sugimoto K, Nakazato K, et al. Electrocardiographic criteria of right ventricular hypertrophy in patients with chronic thromboembolic pulmonary hypertension after balloon pulmonary angioplasty. Intern Med 58: 2139-2144, 2019.","DOI":"10.2169\/internalmedicine.2320-18"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Rice P, Longden I, Bleasby A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16: 276-277, 2000.","DOI":"10.1016\/S0168-9525(00)02024-2"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Brunelli L, Cieslik KA, Alcorn JL, Vatta M, Baldini A. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3 epsilon in human endothelial cells via CCAAT\/enhancer binding protein-\u03b2. Circ Res 100: e59-e71, 2007.","DOI":"10.1161\/01.RES.0000260805.99076.22"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Zheng Z, Yan G, Li X, et al. Lysine crotonylation regulates leucine-deprivation-induced autophagy by a 14-3-3\u03b5-PPM1B axis. Cell Rep 41: 111850, 2022.","DOI":"10.1016\/j.celrep.2022.111850"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wu JS, Cheung WM, Tsai YS, et al. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119: 1124-1134, 2009.","DOI":"10.1161\/CIRCULATIONAHA.108.812537"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Khassafi F, Chelladurai P, Valasarajan C, et al. Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. Nat Cardiovasc Res 2: 917-936, 2023.","DOI":"10.1038\/s44161-023-00338-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Zhang ZJ, Liu C, Ma JL, et al. Prognostic value of plasma immunoglobulin G N-glycome traits in pulmonary arterial hypertension. J Am Coll Cardiol 84: 1092-1103, 2024.","DOI":"10.1016\/j.jacc.2024.05.077"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Yokokawa T, Boucherat O, Martineau S, et al. Prognostic significance of proteomics-discovered circulating inflammatory biomarkers in patients with pulmonary arterial hypertension. J Am Heart Assoc 13: e032888, 2024.","DOI":"10.1161\/JAHA.123.032888"},{"key":"29","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1161\/CIR.0000000000000560","volume":"137","author":"MA Konstam","year":"2018","unstructured":"29. Konstam MA, Kiernan MS, Bernstein D, et al.; the American Heart Association Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Cardiovascular Surgery and Anesthesia. Evaluation and management of right-sided heart failure: a scientific statement from the American Heart Association. Circulation 137: e578-e622, 2018.","journal-title":"Circulation","ISSN":"https:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Park S, Ranjbarvaziri S, Zhao P, Ardehali R. Cardiac fibrosis is associated with decreased circulating levels of full-length CILP in heart failure. JACC Basic Transl Sci 5: 432-443, 2020.","DOI":"10.1016\/j.jacbts.2020.01.016"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6383-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:14:00Z","timestamp":1785557640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/15\/65_6383-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":30,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6383-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"6383-25"}}